Switch theme
Sign up to access all valuation multiples
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
1996
1K+
LTM Revenue $135M
LTM EBITDA -$5.5M
$93.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zynex has a last 12-month revenue (LTM) of $135M and a last 12-month EBITDA of -$5.5M.
In the most recent fiscal year, Zynex achieved revenue of $192M and an EBITDA of $10.8M.
Zynex expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zynex valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $135M | XXX | $192M | XXX | XXX | XXX |
| Gross Profit | $102M | XXX | $153M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$5.5M | XXX | $10.8M | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | 6% | XXX | XXX | XXX |
| EBIT | -$18.0M | XXX | $6.0M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | -$22.6M | XXX | $3.0M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $18.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 1, 2025, Zynex's stock price is $1.
Zynex has current market cap of $38.2M, and EV of $93.1M.
See Zynex trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.1M | $38.2M | XXX | XXX | XXX | XXX | $-0.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 1, 2025, Zynex has market cap of $38.2M and EV of $93.1M.
Zynex's trades at 0.5x EV/Revenue multiple, and 8.6x EV/EBITDA.
Equity research analysts estimate Zynex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zynex has a P/E ratio of -1.7x.
See valuation multiples for Zynex and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38.2M | XXX | $38.2M | XXX | XXX | XXX |
| EV (current) | $93.1M | XXX | $93.1M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | -16.9x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBIT | -5.2x | XXX | 15.5x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | 12.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZynex's last 12 month revenue growth is -27%
Zynex's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Zynex's rule of 40 is -17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zynex's rule of X is -71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zynex and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -27% | XXX | -27% | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 112% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -17% | XXX | -21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zynex acquired XXX companies to date.
Last acquisition by Zynex was XXXXXXXX, XXXXX XXXXX XXXXXX . Zynex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zynex founded? | Zynex was founded in 1996. |
| Where is Zynex headquartered? | Zynex is headquartered in United States of America. |
| How many employees does Zynex have? | As of today, Zynex has 1K+ employees. |
| Who is the CEO of Zynex? | Zynex's CEO is Mr. Thomas Sandgaard. |
| Is Zynex publicy listed? | Yes, Zynex is a public company listed on NAS. |
| What is the stock symbol of Zynex? | Zynex trades under ZYXI ticker. |
| When did Zynex go public? | Zynex went public in 2002. |
| Who are competitors of Zynex? | Similar companies to Zynex include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Zynex? | Zynex's current market cap is $38.2M |
| What is the current revenue of Zynex? | Zynex's last 12 months revenue is $135M. |
| What is the current revenue growth of Zynex? | Zynex revenue growth (NTM/LTM) is -27%. |
| What is the current EV/Revenue multiple of Zynex? | Current revenue multiple of Zynex is 0.7x. |
| Is Zynex profitable? | Yes, Zynex is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zynex? | Zynex's last 12 months EBITDA is -$5.5M. |
| What is Zynex's EBITDA margin? | Zynex's last 12 months EBITDA margin is -4%. |
| What is the current EV/EBITDA multiple of Zynex? | Current EBITDA multiple of Zynex is -16.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
